Halozyme Therapeutics, Inc.
General ticker "HALO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.3B (TTM average)
Halozyme Therapeutics, Inc. follows the US Stock Market performance with the rate: 38.5%.
Estimated limits based on current volatility of 2.9%: low 64.13$, high 67.98$
Factors to consider:
- Total employees count: 350 as of 2024
- Top business risk factors: Regulatory and compliance, Dependence on ENHANZE technology, Public health crises, Transaction risks, Operational and conduct risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [40.57$, 63.80$]
- 2025-12-31 to 2026-12-31 estimated range: [42.23$, 66.58$]
Financial Metrics affecting the HALO estimates:
- Negative: with PPE of 11.2 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 54.32 > 18.64
- Positive: 6.82 < Operating cash flow per share per price, % of 7.95
- Negative: Shareholder equity ratio, % of 17.63 <= 18.93
- Positive: Inventory ratio change, % of -1.08 <= -0.75
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 17.71 > 6.04
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.30 <= 0.79
Short-term HALO quotes
Long-term HALO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $660.12MM | $829.25MM | $1,015.32MM |
| Operating Expenses | $392.58MM | $491.68MM | $463.85MM |
| Operating Income | $267.53MM | $337.57MM | $551.48MM |
| Non-Operating Income | $-18.61MM | $10.76MM | $5.66MM |
| Interest Expense | $16.95MM | $18.76MM | $18.09MM |
| R&D Expense | $66.61MM | $76.36MM | $79.05MM |
| Income(Loss) | $248.92MM | $348.33MM | $557.13MM |
| Taxes | $46.79MM | $66.73MM | $113.04MM |
| Profit(Loss)* | $202.13MM | $281.59MM | $444.09MM |
| Stockholders Equity | $169.80MM | $83.81MM | $363.82MM |
| Inventory | $100.12MM | $127.60MM | $141.86MM |
| Assets | $1,841.51MM | $1,733.27MM | $2,063.48MM |
| Operating Cash Flow | $240.11MM | $388.57MM | $479.06MM |
| Capital expenditure | $4.81MM | $15.29MM | $10.70MM |
| Investing Cash Flow | $-487.00MM | $-96.91MM | $-262.72MM |
| Financing Cash Flow | $362.37MM | $-407.99MM | $-218.86MM |
| Earnings Per Share** | $1.48 | $2.13 | $3.50 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.